Cardiorenal benefits of finerenone: protecting kidney and heart
AbstractPersons with diabetes and chronic kidney disease (CKD) have a high residual risk of developing cardiovascular (CV) complications despite treatment with renin-angiotensin system blockers and sodium-glucose cotransporter type 2 inhibitors. Overactivation of mineralocorticoid receptors plays a...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2023-12-01
|
| Series: | Annals of Medicine |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/07853890.2023.2171110 |
| _version_ | 1827380567607345152 |
|---|---|
| author | José R. González-Juanatey Jose Luis Górriz Alberto Ortiz Alfonso Valle Maria Jose Soler Lorenzo Facila |
| author_facet | José R. González-Juanatey Jose Luis Górriz Alberto Ortiz Alfonso Valle Maria Jose Soler Lorenzo Facila |
| author_sort | José R. González-Juanatey |
| collection | DOAJ |
| description | AbstractPersons with diabetes and chronic kidney disease (CKD) have a high residual risk of developing cardiovascular (CV) complications despite treatment with renin-angiotensin system blockers and sodium-glucose cotransporter type 2 inhibitors. Overactivation of mineralocorticoid receptors plays a key role in the progression of renal and CV disease, mainly by promoting inflammation and fibrosis. Finerenone is a nonsteroidal selective mineralocorticoid antagonist. Recent clinical trials, such as FIDELIO-DKD and FIGARO-DKD and the combined analysis FIDELITY have demonstrated that finerenone decreases albuminuria, risk of CKD progression, and CV risk in subjects with type 2 diabetes (T2D) and CKD. As a result, finerenone should thus be considered as part of a holistic approach to kidney and CV risk in persons with T2D and CKD. In this narrative review, the impact of finerenone treatment on the CV system in persons with type 2 diabetes and CKD is analyzed from a practical point of view.Key messages:Despite inhibition of renin-angiotensin system and sodium-glucose cotransporter type 2, persons with type 2 diabetes (T2D) and chronic kidney disease (CKD) remain on high cardiovascular (CV) residual risk.Overactivation of mineralocorticoid receptors plays a key role in the progression of renal and CV disease, mainly by promoting inflammation and fibrosis that is not targeted by traditional treatments.Finerenone is a nonsteroidal selective mineralocorticoid antagonist that decreases not only albuminuria, but also the risk of CKD progression, and CV risk in subjects with T2D and CKD. |
| first_indexed | 2024-03-08T13:35:48Z |
| format | Article |
| id | doaj.art-d82a89a5da80471fbf7451b2be3b01ef |
| institution | Directory Open Access Journal |
| issn | 0785-3890 1365-2060 |
| language | English |
| last_indexed | 2024-03-08T13:35:48Z |
| publishDate | 2023-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Annals of Medicine |
| spelling | doaj.art-d82a89a5da80471fbf7451b2be3b01ef2024-01-16T19:13:20ZengTaylor & Francis GroupAnnals of Medicine0785-38901365-20602023-12-0155150251310.1080/07853890.2023.2171110Cardiorenal benefits of finerenone: protecting kidney and heartJosé R. González-Juanatey0Jose Luis Górriz1Alberto Ortiz2Alfonso Valle3Maria Jose Soler4Lorenzo Facila5Cardiology Department, Hospital Clínico Universitario Santiago de Compostela, Centro de investigación Biomédica en Red Enfermedades Cardiovasculares (CIBERCV), Santiago de Compostela, SpainNephrology Department, Hospital Clínico Universitario de Valencia, Universidad de Valencia, Valencia, SpainNephrology Department, Fundación Jiménez Díaz, Madrid, SpainCardiology Department, Hospital La Salud, Valencia, SpainNephrology Department, Hospital Universitario Vall d‘Hebron, Barcelona, SpainCardiology Department, Consorcio Hospital General Universitario de Valencia, Valencia, SpainAbstractPersons with diabetes and chronic kidney disease (CKD) have a high residual risk of developing cardiovascular (CV) complications despite treatment with renin-angiotensin system blockers and sodium-glucose cotransporter type 2 inhibitors. Overactivation of mineralocorticoid receptors plays a key role in the progression of renal and CV disease, mainly by promoting inflammation and fibrosis. Finerenone is a nonsteroidal selective mineralocorticoid antagonist. Recent clinical trials, such as FIDELIO-DKD and FIGARO-DKD and the combined analysis FIDELITY have demonstrated that finerenone decreases albuminuria, risk of CKD progression, and CV risk in subjects with type 2 diabetes (T2D) and CKD. As a result, finerenone should thus be considered as part of a holistic approach to kidney and CV risk in persons with T2D and CKD. In this narrative review, the impact of finerenone treatment on the CV system in persons with type 2 diabetes and CKD is analyzed from a practical point of view.Key messages:Despite inhibition of renin-angiotensin system and sodium-glucose cotransporter type 2, persons with type 2 diabetes (T2D) and chronic kidney disease (CKD) remain on high cardiovascular (CV) residual risk.Overactivation of mineralocorticoid receptors plays a key role in the progression of renal and CV disease, mainly by promoting inflammation and fibrosis that is not targeted by traditional treatments.Finerenone is a nonsteroidal selective mineralocorticoid antagonist that decreases not only albuminuria, but also the risk of CKD progression, and CV risk in subjects with T2D and CKD.https://www.tandfonline.com/doi/10.1080/07853890.2023.2171110Albuminuriacardiovascularchronic kidney diseasefinerenoneinflammationtype 2 diabetes |
| spellingShingle | José R. González-Juanatey Jose Luis Górriz Alberto Ortiz Alfonso Valle Maria Jose Soler Lorenzo Facila Cardiorenal benefits of finerenone: protecting kidney and heart Annals of Medicine Albuminuria cardiovascular chronic kidney disease finerenone inflammation type 2 diabetes |
| title | Cardiorenal benefits of finerenone: protecting kidney and heart |
| title_full | Cardiorenal benefits of finerenone: protecting kidney and heart |
| title_fullStr | Cardiorenal benefits of finerenone: protecting kidney and heart |
| title_full_unstemmed | Cardiorenal benefits of finerenone: protecting kidney and heart |
| title_short | Cardiorenal benefits of finerenone: protecting kidney and heart |
| title_sort | cardiorenal benefits of finerenone protecting kidney and heart |
| topic | Albuminuria cardiovascular chronic kidney disease finerenone inflammation type 2 diabetes |
| url | https://www.tandfonline.com/doi/10.1080/07853890.2023.2171110 |
| work_keys_str_mv | AT josergonzalezjuanatey cardiorenalbenefitsoffinerenoneprotectingkidneyandheart AT joseluisgorriz cardiorenalbenefitsoffinerenoneprotectingkidneyandheart AT albertoortiz cardiorenalbenefitsoffinerenoneprotectingkidneyandheart AT alfonsovalle cardiorenalbenefitsoffinerenoneprotectingkidneyandheart AT mariajosesoler cardiorenalbenefitsoffinerenoneprotectingkidneyandheart AT lorenzofacila cardiorenalbenefitsoffinerenoneprotectingkidneyandheart |